Acquisition History / Garda Therapeutics / Assertio Holdings, Inc.
Garda Therapeutics Acquires Assertio Holdings, Inc.
Announced April 9, 2026 — $153.2M
What happened
Assertio agreed on April 8, 2026 to be acquired by Garda Therapeutics for $18.00 per share in cash plus a CVR, and on May 4, 2026 amended the agreement to $21.80 per share in cash, total cash consideration of $153.2M, after a competing approach from Zydus.
- Acquirer
- Garda Therapeutics
- Target
- Assertio Holdings, Inc.
- Announced
- April 9, 2026
- Price
- $153.2M
- Industry
- Specialty pharmaceuticals
- Buyer type
- Strategic acquirer
- Status
- Announced, not yet closed
By the numbers
Frequently Asked Questions About This Acquisition
When did Garda Therapeutics acquire Assertio Holdings, Inc.?
Garda Therapeutics acquired Assertio Holdings, Inc. on April 9, 2026. This was Garda Therapeutics's 1st publicly tracked acquisition out of 1 we have on record.
How much did Garda Therapeutics pay for Assertio Holdings, Inc.?
Garda Therapeutics paid $153.2M for Assertio Holdings, Inc..
What does Assertio Holdings, Inc. do?
Assertio agreed on April 8, 2026 to be acquired by Garda Therapeutics for $18.00 per share in cash plus a CVR, and on May 4, 2026 amended the agreement to $21.80 per share in cash, total cash consideration of $153.2M, after a competing approach from Zydus.
What other Specialty pharmaceuticals companies has Garda Therapeutics acquired?
Assertio Holdings, Inc. is Garda Therapeutics's only publicly tracked acquisition in Specialty pharmaceuticals so far.